341529-34-8

Basic information

• Product Name: (3-NITRO-PHENYL)-PIPERAZIN-1-YL-METHANONE
• Synonyms: AKOS BB-6397;(3-NITRO-PHENYL)-PIPERAZIN-1-YL-METHANONE;1-(3-NITROBENZOYL)-PIPERAZINE;1-(3-Nitro-phenyl)-piperazin-1-yl-methanone;1-(3-Nitrobenzoyl)piperazine 98%;1-(3-NITROBENZOYL)-PIPERAZINE >98%
• CAS NO: 341529-34-8
• Molecular Formula: C₁₁H₁₃N₃O₃
• Molecular Weight: 235.24
• Product Categories: piperazines
• Mol File: 341529-34-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 425.3 °C at 760 mmHg
• Flash Point: 211 °C
• Appearance: /
• Density: 1.289 g/cm³
• Vapor Pressure: 1.93E-07mmHg at 25°C
• Refractive Index: 1.589
• CAS DataBase Reference: (3-NITRO-PHENYL)-PIPERAZIN-1-YL-METHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: (3-NITRO-PHENYL)-PIPERAZIN-1-YL-METHANONE(341529-34-8)
• EPA Substance Registry System: (3-NITRO-PHENYL)-PIPERAZIN-1-YL-METHANONE(341529-34-8)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 341529-34-8(Hazardous Substances Data)

Usage

General Description

(3-Nitro-phenyl)-piperazin-1-yl-methanone is a chemical compound that consists of a piperazine ring with a phenyl moiety and a nitro group attached to it. It is commonly used as a building block in the synthesis of various pharmaceuticals and research chemicals. (3-NITRO-PHENYL)-PIPERAZIN-1-YL-METHANONE has shown potential as a serotonin receptor agonist and has been studied for its potential applications in the treatment of neurological and psychiatric disorders. Additionally, it has been investigated for its potential use in drug design and in the development of new therapeutic agents. However, it is important to handle this chemical with care, as it may pose health hazards if not handled properly.

InChI:InChI=1/C11H13N3O3/c15-11(13-6-4-12-5-7-13)9-2-1-3-10(8-9)14(16)17/h1-3,8,12H,4-7H2

Upstream product

• 110-85-0 piperazine 
• 389628-56-2 tert-butyl 4-(3-nitrobenzoyl)piperazine-1-carboxylate 
• 121-90-4 m-nitrobenzoic acid chloride 
• 121-92-6 3-nitrobenzoic acid 

Relevant articles and documents

N-Acylbenzotriazole: convenient approach for protecting group-free monoacylation of symmetric diamines

Abstract: An efficient green route for monoacylation of aromatic diamines, namely o-phenylenediamine and p-phenylenediamine and aliphatic diamines ethylenediamine and piperazine using N-acylbenzotriazoles (NABs) in n-butanol was developed. The new protocol does not require prior selective protection of the diamine and comprises simple conditions, short reaction times, an easy work up as well as high isolated yields (69–94%). Moreover, the method described herein enable stepwise acylation of aliphatic diamines such as ethylenediamine and piperazine with two different N-acylbenzotriazoles affording unsymmetrical substituted diamines that can be used for construction of pharmaceutically important targets such as drugs, foldamers, and drug conjugates. Graphic abstract: [Figure not available: see fulltext.]

Thienopyrimidinone compound and use thereof

The invention belongs to the field of chemical medicines and specifically relates to a thienopyrimidinone compound. The thienopyrimidinone compound has a structural formula shown in the description. The novel thienopyrimidinone compound can produce good inhibition effects on Tankyrase, has no obvious toxicity, can obviously inhibit the proliferation of tumor cells after STF3A cell treatment basedon the compound, has the good medicinal potential and provides a novel potential choice for clinical medication. The novel thienopyrimidinone compound can improve the expression level of an axin in the wnt signal pathway, induce the degradation of beta-catenin, thereby inhibiting the proliferation of tumor cells, can be used as a clinical prodrug candidate compound for various tumor cells and hasfurther research and development potential. A preparation method of the thienopyrimidinone compound can produce the compound with a high yield and high biological activity. The thienopyrimidinone compound has significant drug properties and has broad market prospects.

Synthesis, characterization, and anti-inflammatory activities of methyl salicylate derivatives bearing piperazine moiety

In this study, a new series of 16 methyl salicylate derivatives bearing a piperazine moiety were synthesized and characterized. The in vivo anti-inflammatory activities of target compounds were investigated against xylol-induced ear edema and carrageenan-induced paw edema in mice. The results showed that all synthesized compounds exhibited potent anti-inflammatory activities. Especially, the anti-inflammatory activities of compounds M15 and M16 were higher than that of aspirin and even equal to that of indomethacin at the same dose. In addition, the in vitro cytotoxicity activities and anti-inflammatory activities of four target compounds were performed in RAW264.7 macrophages, and compound M16 was found to significantly inhibit the release of lipopolysaccharide (LPS)-induced interleukin (IL)-6 and tumor necrosis factor (TNF)-α in a dose-dependent manner. In addition, compound M16 was found to attenuate LPS induced cyclooxygenase (COX)-2 up-regulation. The current preliminary study may provide information for the development of new and safe anti-inflammatory agents.